RD-Biotech Expands Antibody and Immunoassay Services with xMAP^® Technology

Joining Luminex’s Licensed Technologies Group enhanced the company’s capabilities

Our Licensed Technologies Group represents a who’s who of companies delivering impressive results by applying Luminex’s xMAP^® Technology to a wide variety of experiments. One of our newest partners is RD-Biotech, a service provider based in France. The talented RD-Biotech team helps clients with services in immunology, molecular biology, and cellular engineering.

Small team, big impact

Founded in 2002, the company works primarily with pharmaceutical and biotech companies interested in outsourcing pre-clinical or clinical tasks for their research and development programs. While the team is small—with a staff of 40—its impact is sizable: RD-Biotech has 200 clients on their roster.

“We are very active with pharmaceutical and biotech companies,” says CEO Philippe Dulieu. “We do what they cannot do internally.” Common services RD-Biotech handles include antibody development, engineering, and manufacturing; conjugating antibodies to beads; and immunoassay development.

New ventures

Recently, Dulieu and his colleagues got a request from a pharmaceutical client working on vaccine development: could they conjugate antibodies to beads for use with xMAP analyzers? The team got started with small batches of beads and quickly ramped up as the project expanded.

Now, RD-Biotech works directly with Luminex as a Licensed Technologies Partner, which Dulieu says gives his team better access to reagents and customer support. They’re already looking to expand their service offerings around xMAP Technology, and purchased a Luminex^® 200™ System, which has allowed them to utilize xMAP kits and deliver results. “We have been able to develop our business with this technology,” Dulieu says.

If you’re interested in learning more about how xMAP Technology can improve your multiplex immunoassays, visit our website.

For Research Use Only. Not for use in diagnostic procedures.